Coagulopathies in intensive care medicine

• Verfasst von: Neuenfeldt, Friederike S. [VerfasserIn]
• Verfasst von: Weigand, Markus A. [VerfasserIn]
• Verfasst von: Fischer, Dania [VerfasserIn]
• Titel: Coagulopathies in intensive care medicine
• Titelzusatz: balancing act between thrombosis and bleeding
• Verf.angabe: Friederike S. Neuenfeldt, Markus A. Weigand and Dania Fischer
• E-Jahr: 2021
• Jahr: 18 November 2021
• Umfang: 17 S.
• Fussnoten: Gesehen am 16.12.2021 ; This article belongs to the special issue "Patient blood management in critical care medicine"
• Titel Quelle: Enthalten in: Journal of Clinical Medicine
• Ort Quelle: Basel : MDPI, 2012
• Jahr Quelle: 2021
• Band/Heft Quelle: 10(2021), 22, special issue, Artikel-ID 5369, Seite 1-17
• ISSN Quelle: 2077-0383
• DOI: doi:10.3390/jcm10225369
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: bleeding
• Sach-SW: coagulation
• Sach-SW: coagulopathy
• Sach-SW: critical care
• K10plus-PPN: 1782375848

Abstract

Patient Blood Management advocates an individualized treatment approach, tailored to each patient’s needs, in order to reduce unnecessary exposure to allogeneic blood products. The optimization of hemostasis and minimization of blood loss is of high importance when it comes to critical care patients, as coagulopathies are a common phenomenon among them and may significantly impact morbidity and mortality. Treating coagulopathies is complex as thrombotic and hemorrhagic conditions may coexist and the medications at hand to modulate hemostasis can be powerful. The cornerstones of coagulation management are an appropriate patient evaluation, including the individual risk of bleeding weighed against the risk of thrombosis, a proper diagnostic work-up of the coagulopathy’s etiology, treatment with targeted therapies, and transfusion of blood product components when clinically indicated in a goal-directed manner. In this article, we will outline various reasons for coagulopathy in critical care patients to highlight the aspects that need special consideration. The treatment options outlined in this article include anticoagulation, anticoagulant reversal, clotting factor concentrates, antifibrinolytic agents, desmopressin, fresh frozen plasma, and platelets. This article outlines concepts with the aim of the minimization of complications associated with coagulopathies in critically ill patients. Hereditary coagulopathies will be omitted in this review.